Atlas Trials

ARCAGY/ GINECO GROUP

51 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch ARCAGY/ GINECO GROUP

RecordFirmDate
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer (NCT07763496)ARCAGY/ GINECO GROUP2026-10-01
Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer (NCT07637851)ARCAGY/ GINECO GROUP2026-08-01
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS (NCT06715241)ARCAGY/ GINECO GROUP2024-12-11
Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study (NCT06599463)ARCAGY/ GINECO GROUP2024-08-19
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery (NCT06476184)ARCAGY/ GINECO GROUP2024-07-30
Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer (NCT06660147)ARCAGY/ GINECO GROUP2023-12-11
Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma (NCT05364905)ARCAGY/ GINECO GROUP2022-05-09
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line (NCT05201547)ARCAGY/ GINECO GROUP2022-04-15
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer (NCT05183984)ARCAGY/ GINECO GROUP2022-02-01
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC (NCT04713514)ARCAGY/ GINECO GROUP2021-08-05
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT (NCT04602377)ARCAGY/ GINECO GROUP2021-08-04
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (NCT03651206)ARCAGY/ GINECO GROUP2020-07-15
COL Immunotherapy Before Radiochimio + Ipilimumab (NCT04256213)ARCAGY/ GINECO GROUP2020-07-02
Genomic BRCA and Extensive ovArian Cancer Testing (NCT04027868)ARCAGY/ GINECO GROUP2019-12-06
NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. (NCT03752216)ARCAGY/ GINECO GROUP2019-04-03
Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse (NCT04015739)ARCAGY/ GINECO GROUP2019-03-01
UTOLA: UTerin OLAparib (NCT03745950)ARCAGY/ GINECO GROUP2019-02-01
PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer . (NCT03275506)ARCAGY/ GINECO GROUP2018-02-26
Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (NCT03249142)ARCAGY/ GINECO GROUP2017-10-18

Track ARCAGY/ GINECO GROUP automatically

Every clearance here is in the API, with alerts when new ones post.